<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Powers, Jenny</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Márquez-Medina, Diego</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Benefit and Tolerance to Induction Therapy in Elderly Patients with Locally Advanced NSCLC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">Elderly patients with locally advanced non-small cell lung cancer (NSCLC) could present similar benefit and tolerance as their younger counterparts to induction chemotherapy (CT) or chemoradiotherapy (CRT) followed by either surgical resection or consolidation radiotherapy. The elderly population is growing and that half of lung cancers are diagnosed in patients older than 60 years [Gridelli C et al. Crit Rev Oncol Hematol 2002]. However, elderly patients are seldom included in multimodal programs of induction CT or CRT [Gridelli C et al. Crit Rev Oncol Hematol 2002].</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>